The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...
New insulin treatments for diabetes are hitting the market fast and furious these days. Biocon Biologics’ effort to move its insulin through the approval process in India, however, has landed the ...
BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...
Biocon share price has rallied over 20% in one month and has gained 17% in three months. The stock has surged 28% in six ...
Bengaluru: As Biocon prepares for a leadership transition on April 1, newly designated CEO and MD Shreehas Tambe has outlined ...
Did our AI summary help? Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it ...
China's auto exports are estimated to slow notably this year after holding the export crown for a second year in 2024, with no growth predicted for electric vehicle exports, an auto association ...
NDTV Profit on MSN
Biocon to benefit after Eli Lilly joins Novo Nordisk to exit European insulins market
The Bengaluru-based drugmaker has approvals for biosimilar versions of Insulin Glargine, Insulin Aspart and Human Insulin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results